Antibiotic-dependent correlation between drug-induced killing and loss of luminescence in Streptococcus gordonii expressing luciferase

被引:9
作者
Loeliger, B [1 ]
Caldelari, I [1 ]
Bizzini, A [1 ]
Meier, PS [1 ]
Majcherczyk, PA [1 ]
Moreillon, P [1 ]
机构
[1] CHU Vaudois, Dept Internal Med, Div Infect Dis, CH-1011 Lausanne, Switzerland
来源
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE | 2003年 / 9卷 / 02期
关键词
D O I
10.1089/107662903765826705
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Measuring antibiotic-induced killing relies on time-consuming biological tests. The firefly luciferase gene (luc) was successfully used as a reporter gene to assess antibiotic efficacy rapidly in slow-growing Mycobacterium tuberculosis. We tested whether luc expression could also provide a rapid evaluation of bactericidal drugs in Streptococcus gordonii. The suicide vectors pFW5luc and a modified version of pJDC9 carrying a promoterless luc gene were used to construct transcriptional-fusion mutants. One mutant susceptible to penicillin-induced killing (LMI2) and three penicillin-tolerant derivatives (LMI103, LMI104, and LMI105) producing luciferase under independent streptococcal promoters were tested. The correlation between antibiotic-induced killing and luminescence was determined with mechanistically unrelated drugs. Chloramphenicol (20 times the MIC) inhibited bacterial growth. In parallel, luciferase stopped increasing and remained stable, as determined by luminescence and Western blots. Ciprofloxacin (200 times the MIC) rapidly killed 1.5 log(10) CFU/ml in 2-4 hr. Luminescence decreased simultaneously by 10-fold. In contrast, penicillin (200 times the MIC) gave discordant results. Although killing was slow (less than or equal to 0.5 log(10) CFU/ml in 2 hr), luminescence dropped abruptly by 50-100-times in the same time. Inactivating penicillin with penicillinase restored luminescence, irrespective of viable counts. This was not due to altered luciferase expression or stability, suggesting some kind of post-translational modification. Luciferase shares homology with aminoacyl-tRNA synthetase and acyl-CoA ligase, which might be regulated by macromolecule synthesis and hence affected in penicillin-inhibited cells. Because of resemblance, luciferase might be down-regulated simultaneously. Luminescence cannot be universally used to predict antibiotic-induced killing. Thus, introducing reporter enzymes sharing mechanistic similarities with normal metabolic reactions might reveal other effects than those expected.
引用
收藏
页码:123 / 131
页数:9
相关论文
共 35 条
[1]  
Amsterdam D., 1996, Antibiotics in laboratory medicine, V6th ed.
[2]   Deregulation of the arginine deiminase (arc) operon in penicillin-tolerant mutants of Streptococcus gordonii [J].
Caldelari, I ;
Loeliger, B ;
Langen, H ;
Glauser, MP ;
Moreillon, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (10) :2802-2810
[3]  
CALDELARI I, 1999, 39 INT C ANT AG CHEM, P127
[4]   Crystal structure of firefly luciferase throws light on a superfamily of adenylate-forming enzymes [J].
Conti, E ;
Franks, NP ;
Brick, P .
STRUCTURE, 1996, 4 (03) :287-298
[5]  
DELUCA M, 1978, METHOD ENZYMOL, P9
[6]  
DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870
[7]   Importance of genotypic and phenotypic tolerance in the treatment of experimental endocarditis due to Streptococcus gordonii [J].
Entenza, JM ;
Caldelari, I ;
Glauser, MP ;
Francioli, P ;
Moreillon, P .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (01) :70-76
[8]   Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans group streptococci [J].
Entenza, JM ;
Caldelari, I ;
Glauser, MP ;
Moreillon, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (06) :775-786
[9]   ADENOSINE TRIPHOSPHATE POOL DURING GROWTH CYCLE IN STREPTOCOCCUS FAECALIS [J].
FORREST, WW .
JOURNAL OF BACTERIOLOGY, 1965, 90 (04) :1013-&
[10]   Monitoring bioluminescent Staphylococcus aureus infections in living mice using a novel luxABCDE construct [J].
Francis, KP ;
Joh, D ;
Bellinger-Kawahara, C ;
Hawkinson, MJ ;
Purchio, TF ;
Contag, PR .
INFECTION AND IMMUNITY, 2000, 68 (06) :3594-3600